Strategies to reduce use of antidepressants
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Antidepressant prescribing has increased year on year since the introduction of the selective serotonin reuptake inhibitors (SSRIs) in the 1980s. More than 10% of adults in England are now taking antidepressants for depression/anxiety, with a median length of treatment of more than 2 years, but antidepressants can cause side effects and withdrawal symptoms which increase with longer use. Surveys of antidepressant users suggest 30–50% have no evidence‐based indication to continue, but coming off antidepressants is often difficult due to fears of relapse, withdrawal symptoms and a lack of psychological treatments to replace maintenance treatment and prevent relapse. GPs should not prescribe antidepressants routinely for mild depressive/anxiety symptoms. Patients starting antidepressants should be advised that they are to be taken for a limited period only, and that there is a risk of withdrawal problems on stopping them. Prescribers should actively review long‐term antidepressant use and suggest coming off them slowly to patients who are well. The relationship between SSRI dose and serotonin transporter receptor occupancy suggests that hyperbolic tapering regimes may be helpful for patients with troubling withdrawal symptoms who cannot stop treatment within 4–8 weeks, and tapering strips can allow carefully titrated slower dose reduction over some months. Internet and telephone support to patients wanting to reduce their antidepressants is being trialled in the REDUCE programme. More research is needed to establish the incidence of withdrawal symptoms in representative samples of patients coming off antidepressants, and large randomised controlled trials are needed to test different tapering strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“pressants are appropriate for some patients to reduce the risk of relapse.(26,27) The National Institute for Health and Care Excellence (NICE) recommends treating people for 2 years in the first instance if”
BackgroundAntidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833 · cited 3×
“sants could account for some of the associations between them and the adverse outcomes.(16) In up to a half of patients, long-term treatment may blunt their ability to feel emotions.”
BackgroundInfluentialMindfulness-based cognitive therapy to prevent relapse in recurrent depression.
Kuyken, W., Byford, S., Taylor, R. S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013786 · Cited by 770
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 1×
“The SSRIs frequently cause significant weight change, sleep disturbance and sexual dysfunction.(15) Anti-”
BackgroundPatient Barriers to and Enablers of Deprescribing: a Systematic Review
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M. S., & Wiese, M. D. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0106-8 · Cited by 536 · cited 1×
“Psychological therapies may work by providing support to patients to manage fears of withdrawal, relapse and lack of selfefficacy, which are possible barriers to discontinuation.(64) 28 KENDRICK”
BackgroundPrevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“Anxiety, mood swings and sleep disturbance may appear to be a recurrence of the original problem requiring treatment.(20) Restarting medication, before withdrawal”
BackgroundSix-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Conti, S., & Grandi, S. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1872 · Cited by 392 · cited 1×
“showed significantly lower risks of recurrence with CBT and tapering vs clinical management and tapering after 2 years (15% vs 35% and 25% vs 80% respectively),(50,57,58) and after 6 years (40% vs 75% and 50% vs 90% respectively).(50,59,60) Meta-analysis of two studies by Kuyken et al.”
ResultDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature
Lacasse, J. R., & Leo, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020392 · Cited by 377 · cited 1×
“The rationale for taking SSRIs commonly presented in drug advertisements, and by GPs at initiation of treatment, is a deficiency of serotonin in the brain [40-42], but giving patients this justification is not supported by evidence from brain studies [40, 43] and should be avoided, as patients may conclude they must t…”
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299 · cited 1×
“showed significantly lower risks of recurrence with CBT and tapering vs clinical management and tapering after 2 years (15% vs 35% and 25% vs 80% respectively),(50,57,58) and after 6 years (40% vs 75% and 50% vs 90% respectively).(50,59,60) Meta-analysis of two studies by Kuyken et al.”
ResultMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
Self-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281 · cited 1×
“The rationale for taking SSRIs commonly presented in drug advertisements, and by GPs at initiation of treatment, is a deficiency of serotonin in the brain [40-42], but giving patients this justification is not supported by evidence from brain studies [40, 43] and should be avoided, as patients may conclude they must t…”
BackgroundTapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280 · cited 10×
“org/GRAC/ObjectDisplayForward?objectId=928) and noted it is a hyperbolic relationship, dropping slowly as doses are halved and quartered, but then more sharply down through the range of doses lower than the minimum therapeutic dose [53].”
BackgroundInfluentialCognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266 · cited 2×
“Psychological support for patients to manage without drug treatment The systematic review of interventions to support discontinuation of antidepressants [50] identified six reports of RCTs of psychological or psychiatric treatment plus drug tapering which led to relatively high antidepressant cessation rates of betwee…”
BackgroundMethodMojtabai, R., & Olfson, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08443 · Cited by 247
Kendrick, T., Dowrick, C., McBride, A., Howe, A., Clarke, P., Maisey, S., Moore, M., & Smith, P. W. (2009) · BMJ · doi:10.1136/bmj.b750 · Cited by 231 · cited 1×
“Lundbeck, Servier, and Wyeth pharmaceuticals for the 2009 study of GP management of depression following the introduction of the QOF indicator.(47) He has received no other funding from pharmaceutical”
BackgroundSelf-citationSim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · cited 3×
“pressants are appropriate for some patients to reduce the risk of relapse.(26,27) The National Institute for Health and Care Excellence (NICE) recommends treating people for 2 years in the first instance if”
BackgroundEmotional blunting with antidepressant treatments: A survey among depressed patients
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.048 · Cited by 202 · cited 1×
“In up to a half of patients, long-term treatment may blunt their ability to feel emotions.(17) Treatment may also impair a person's autonomy and resilience, increasing their dependence on medical help, so no patients should be treated unnecessarily.”
BackgroundDowrick, C., & Frances, A. (2013) · BMJ · doi:10.1136/bmj.f7140 · Cited by 167 · cited 1×
“depression [9, 10] are not borne out by these studies which show the proportion of patients”
BackgroundBatelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017) · BMJ · doi:10.1136/bmj.j3927 · Cited by 153
Prevalence, duration and indications for prescribing of antidepressants in primary care
Petty, D. R., House, A., Knapp, P., Raynor, T., & Zermansky, A. (2006) · Age and Ageing · doi:10.1093/ageing/afl023 · Cited by 110 · cited 1×
“The median duration of use among patients on antidepressants is now more than two years in the UK [11, 12] and more than five years in the USA [13, 14], which is ahead of us in this process of ever-increasing length of treatment.”
BackgroundRecognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study
Johnson, C. F., Macdonald, H. J., Atkinson, P., Buchanan, A. I., Downes, N., & Dougall, N. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x658304 · Cited by 105 · cited 1×
“However, an uncontrolled trial of pharmacistprompted GP review of long-term users in Scotland resulted in only 7% of patients stopping their antidepressants, although an additional 13% did reduce the dose.(12) Similarly, prompting GPs to review patients eligible for withdrawal was tested in an RCT in the Netherlands a…”
BackgroundA review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
Maund, E., Dewar-Haggart, R., Williams, S., Bowers, H., Geraghty, A. W. A., Leydon, G., May, C., Dawson, S., & Kendrick, T. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.107 · Cited by 90 · cited 4×
“Bowers, drawing on theory, evidence and in-depth systematic qualitative research with patients.(49,70) The aim is to increase patients' selfefficacy for stopping antidepressants in a way that is safe and suited”
BackgroundInfluentialSelf-citationLeydon, G. M., Rodgers, L., & Kendrick, T. (2007) · Family Practice · doi:10.1093/fampra/cmm069 · Cited by 85
Self-citationManaging antidepressant discontinuation: a systematic review
Maund, E., Stuart, B., Moore, M., Dowrick, C., Geraghty, A. W. A., Dawson, S., & Kendrick, T. (2019) · The Annals of Family Medicine · doi:10.1370/afm.2336 · Cited by 82 · cited 7×
“A systematic review of interventions to support discontinuation of antidepressants found that the risk of withdrawal symptoms is higher with abrupt termination of antidepressants.(50) Until recently, NICE and other guidelines recommended relatively rapid tapering, over 2–4 weeks, halving doses and perhaps halving agai…”
BackgroundResultInfluentialSelf-citationVerbeek-Heida, P. M., & Mathot, E. F. (2006) · Chronic Illness · doi:10.1177/17423953060020020801 · Cited by 75
Long-term prescribing of antidepressants in the older population: a qualitative study
Dickinson, R., Knapp, P., House, A. O., Dimri, V., Zermansky, A., Petty, D., Holmes, J., & Raynor, D. K. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483913 · Cited by 66
Ambresin, G., Palmer, V., Densley, K., Dowrick, C., Gilchrist, G., & Gunn, J. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.055 · Cited by 61
Himei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56
Eveleigh, R., Speckens, A., van Weel, C., Oude Voshaar, R., & Lucassen, P. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319872344 · Cited by 48 · cited 1×
“The rationale for taking SSRIs commonly presented in drug advertisements, and by GPs at initiation of treatment, is a deficiency of serotonin in the brain, but giving patients this justification is not supported by evidence from brain studies(40,43) and should be avoided, as patients may conclude they must therefore r…”
BackgroundBowers, H. M., Williams, S. J., Geraghty, A. W. A., Maund, E., O’brien, W., Leydon, G., May, C. R., & Kendrick, T. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027837 · Cited by 31 · cited 2×
“RP-PG-1214-20004), has identified barriers and facilitators to stopping antidepressants through qualitative research with patients and practitioners [49,68] and used this to inform the design of Internet patient and practitioner support packages”
BackgroundSelf-citationTapering of SSRI treatment to mitigate withdrawal symptoms
Ruhe, H. G., Horikx, A., van Avendonk, M. J. P., Groeneweg, B. F., & Woutersen-Koch, H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30182-8 · Cited by 28 · cited 7×
“Independent of Horowitz and Taylor(53) but with identical reasoning, they proposed reducing doses hyperbolically, and also advocated mini-tapering.(54)”
BackgroundInfluentialEveleigh, R., Grutters, J., Muskens, E., Oude Voshaar, R., van Weel, C., Speckens, A., & Lucassen, P. (2014) · Family Practice · doi:10.1093/fampra/cmu043 · Cited by 28 · cited 1×
“discontinuing antidepressants in the intervention group compared to 8% in the control group.(31,32) Prompting the prescriber to review treatment seems, therefore,”
Research works printed but not linked: 29
- 10.1136/bmj.f7261 · DOI
- Taylor S, 2019, Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review
- 10.1007/s00228-004-0726-3 · DOI
- 10.1192/bjp.bp.115.166975 · DOI · Paper page
- 10.1016/j.jad.2015.03.040 · DOI
- Spence R, 2014, Antidepressant Prescribing: Trends in the Prescribing of Antidepressants in Primary Care
- 10.1136/bmj.f191 · DOI · Paper page
- Pratt LA, 2011, Antidepressant use in persons aged 12 and over: United States, 2005–2008, NCHS Data Brief, 76, 1
- Middleton DJ, 2011, Continuity and monitoring of antidepressant therapy in a primary care setting, Qual Prim Care, 19, 109
- 10.1093/fampra/cmu019 · DOI
- 10.1136/bmj.g228 · DOI
- Cruickshank G, 2008, Cross‐sectional survey of patients in receipt of long‐term repeat prescriptions for antidepressant drugs in primary care, Ment Health Fam Med, 5, 105
- EveleighRH.Inappropriate long‐term antidepressant use in primary care: a challenge to change (PhD thesis). Nijmegen: Radboud University;2015.
- ManginD DowsonC MulderR et al.The effectiveness of maintenance SSRI treatment in primary care depression to prevent recurrence: multicentre double blinded placebo controlled RCT. Proceedings of the 2015 North American Primary Care Research Group (NAPCRG) 43rd Annual Meeting.
- 10.1192/bjp.bp.111.104257 · DOI · Paper page
- McCrone P, 2008, Paying the Price: The Cost of Mental Health Care in England to 2026, 15
- 10.1001/archinte.166.10.1092 · DOI · Paper page
- 10.3399/bjgp18X695681 · DOI
- 10.1016/j.jad.2015.06.052 · DOI
- 10.3399/bjgp09X454061 · DOI
- Groot PC, 2013, Taperingstrips voor paroxetine en venlafaxine, Tijdschr Psychiatr, 55, 789
- 10.1080/17522439.2018.1469163 · DOI · Paper page
- 10.3310/hta19730 · DOI · Paper page
- 10.1192/bjp.bp.115.168971 · DOI · Paper page
- 10.3399/bjgp13X671641 · DOI
- 10.1186/s13063-020-04338-7 · DOI · Paper page
- 10.1136/bmjopen-2019-032312 · DOI
- 10.1093/nar/gkx1121 · DOI · Paper page
- 10.1111/bph.13883 · DOI · Paper page
Cited by
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
Amrein, M. A., Hengartner, M. P., Näpflin, M., Farcher, R., & Huber, C. A. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03559-4 · Cited by 23
“However, recent literature indicates that a higher number of AD prescriptions is mainly due to a higher number of long-term users [11, 12].”
BackgroundMunro, N. R., Teague, S., Somoray, K., Simpson, A., Budden, T., Jackson, B., Rebar, A., & Dimmock, J. (2026) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-110301 · Cited by 23
Metadata
- Authors
- Kendrick, T.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2020-07-27
- Volume
- 87
- Issue
- 1
- Pages
- 23-33
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W3040894952
- Cited by
- 96
- References
- 38
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Funders
- Programme Grants for Applied Research (RP‐PG‐1214‐20004)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.